Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301).

Next Previous
X
Search
Trial Profile

A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301).

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tarlatamab (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms DeLLphi-301
  • Sponsors Amgen

    • Most Recent Events

    • 09 Sep 2024 Results (n=100) published in the Amgen Media Release.
    • 09 Sep 2024 According to an Amgen media release, the company announced the presentation of long-term results from the Phase 2 DeLLphi-301 study as an oral presentation at the 2024 World Conference on Lung Cancer (WCLC) in San Diego.
    • 06 Aug 2024 According to an Amgen media release, long-term follow-up data from this study will be presented at the 2024 World Conference on Lung Cancer (WCLC) this fall.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top